Dergiler / Hacettepe Journal of Biology and Chemistry / 2022 / Cilt: 50 - Sayı: 1

ENHANCED ANTICANCER POTENCY OF GEMCITABINE IN COMBINATION WITH PROPOFOL IN PROSTATE CANCER

Sayfa
1–12
Yayın Tarihi
2022-01-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

According to the results obtained from the western blot analysis, the combination of these two agents was found to lead to synergistic inhibition of the PI3K/Akt/mTOR pathway.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:For this purpose, the use of anesthetic agents is considered as a new alternative.
📊
Temel Bulgular & Veri:Therefore, in the present study, the effects of propofol which is an intravenous anesthetic on its own and simultaneously with gemcitabine were investigated on human prostate cancer brain metastasis DU145 and bone metastasis PC3 cells at both cellular and molecular levels.
💡
Sonuç & Katkı:According to the results obtained from the western blot analysis, the combination of these two agents was found to lead to synergistic inhibition of the PI3K/Akt/mTOR pathway.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:cytotoxicity · gemcitabine · propofol

Abstract

For this purpose, the use of anesthetic agents is considered as a new alternative. Therefore, in the present study, the effects of propofol which is an intravenous anesthetic on its own and simultaneously with gemcitabine were investigated on human prostate cancer brain metastasis DU145 and bone metastasis PC3 cells at both cellular and molecular levels. In the first stage of our study, toxic doses of these agents were determined by using the CVDK-8 and lactate dehydrogenase release test. In the following phases, TAC and TOS analyzes were performed to determine the biochemical effects of these agents on cell lines, and also western blot analysis was used to show the inhibition of important oncogenic PI3K/AKT/mTOR pathway in cells treated with these agents. Propofol was found to increase the effectiveness of gemcitabine in both cells. When propofol and gemcitabine were administered simultaneously at high concentrations, they reduced cell viability and increased LDH activity. According to the results obtained from the western blot analysis, the combination of these two agents was found to lead to synergistic inhibition of the PI3K/Akt/mTOR pathway.

🔖

Bu Makaleye Atıf Yap

KARATAŞ, E. A., BAYINDIRLI, K. (2022). ENHANCED ANTICANCER POTENCY OF GEMCITABINE IN COMBINATION WITH PROPOFOL IN PROSTATE CANCER. Hacettepe Journal of Biology and Chemistry, Cilt: 50 - Sayı: 1, 1–12. https://ajindex.com/articles/669141

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. K. Hariharan, V. Padmanabha, Demography and disease characteristics of prostate cancer in India, Indian J. Urol., 32 (2016) 103-108
  2. C.H. Pernar, E.M. Ebot, K.M. Wilson, L.A. Mucci, The epidemiology of prostate cancer, Cold Spring Harb. Perspect. Med., 8 (2018) a030361
  3. M.C. Markowski, M.A. Carducci, Early use of chemotherapy in metastatic prostate cancer, Cancer Treat, Rev., 55 (2017) 218-224
  4. H.J. Lavery, M.R. Cooperberg, Clinically localized prostate cancer in 2017: A review of comparative effectiveness, Urol. Oncol., 35 (2017) 40-41
  5. J. Song, Y. Song, W. Guo, J. Jia, Y. Jin, A. Bai, Regulatory roles of KDR antisense oligonucleotide on the proliferation of human prostate cancer cell line PC-3, J. BUON., 19 (2014) 770-774
  6. T. Jurić, J.S. Katanić Stanković, G. Rosić, D. Selaković, J. Joksimović, D. Mišić, V. Stanković, V. Mihailović, Protective effects of Alchemilla vulgaris L. extracts against cisplatin-induced toxicological alterations in rats, South African Journal of Botany, 128 (2020) 141-151
  7. Q.H. Du, Y.B. Xu, M.Y. Zhang, P. Yun, C.Y. He, Propofol induces apoptosis and increases gemcitabine sensitivity in pancreatic cancer cells in vitro by inhibition of nuclear factor-κB activity, World J. Gastroenterol., 19 (2013) 5485-5492
  8. V. Fodale, M.G. D’Arrigo, S. Triolo, S. Mondello, D. La Torre, Anesthetic techniques and cancer recurrence after surgery", The Scientific World Journal, 5 (2014) 328513
  9. W. Yang, J. Cai, C. Zabkiewicz, H. Zhang, F. Ruge, W.G. Jiang, The effects of anesthetics on recurrence and metastasis of cancer, and clinical implications, World J. Oncol., 8 (2017) 63-70
  10. J. Song, Y. Shen, J. Zhang, Q. Lian, Mini profile of potential anticancer properties of propofol. PLoS One, 9 (2014) e114440
  11. T. Mammoto, M. Mukai, A. Mammoto, Y. Yamanaka, Y. Hayashi, T. Mashimo, Y. Kishi, H. Nakamura, Intravenous anesthetic, propofol inhibits invasion of cancer cells, Cancer Lett., 18 (2002) 165-170
  12. R. Melamed, S. Bar-Yosef, G. Shakhar, S. Ben-Eliyahu, Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures, Anesth. Analg. 97 (2003) 1331-1339
  13. R.A. Siddiqui, M. Zerouga, M. Wu, A. Castillo, K. Harvey, G.P Zaloga, W. Stillwell, Anticancer properties of propofoldocosahexaenoate and propofol-eicosapentaenoate on breast cancer cells, Breast Cancer Res.,7 (2005) 645-654
  14. J. Homburger, S